key: cord-0852159-q15bufg9 authors: Dworakowska, Dorota; Morley, Simon; Mulholland, Nicola; Grossman, Ashley B title: Covid‐19 related thyroiditis: a novel disease entity? date: 2021-03-02 journal: Clin Endocrinol (Oxf) DOI: 10.1111/cen.14453 sha: f7a8ef0b7ca98173dfd0e7dff87bf0ada2ba5b73 doc_id: 852159 cord_uid: q15bufg9 The literature on COVID‐19‐related thyroid complications has accumulated over the past year or so as the pandemic has accelerated throughout the world. In particular, several recent case reports have been published describing a possible correlation between COVID‐19 disease and subacute thyroiditis (SAT). In this review, we briefly present one of our own patients and review the current published literature in this area up to January 2021, including analyses of major series of thyroid function tests in patients with significant COVID‐19 infection. We conclude that while the great majority of patients with severe COVID‐19 infection may show manifestations of the sick euthyroid syndrome, clinicians should be aware of the possibility of SAT, especially in the early weeks and months following even mild COVID‐19 infection. The COVID-19 pandemic has affected all aspects of our lives worldwide, causing a tremendous strain on healthcare services, affecting directly and indirectly the course and treatment of many common illnesses. Each medical specialty continues supporting their patients with COVID-19-related illnesses and their consequences [1] [2] [3] [4] [5] [6] [7] , and several recent authoritative reviews have been published in specific areas of endocrinology 1, 3, 4, [6] [7] [8] [9] [10] . At the beginning of this year, most authors were trying to translate experience from the SARS-CoV pandemic from 2002 to COVID-19, as few data were available on COVID-19 itself. In terms of thyroid function and COVID-19, management strategies for thyroid disease have been published 11 and we have reviewed earlier data based on publications up to March 2020 10 . However, over recent months the number of COVID-19-related papers has greatly increased, principally based on case reports as well as retrospective analyses [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . We now review the current situation, beginning with an illustrative case history of one of our patients, and emphasising the apparent relationship between COVID-19 infection and subacute thyroiditis (SAT). A 57 year-old Caucasian lady presented in July 2020 for a remote thyroid review to one of us (D.D.): her referral was triaged before accepting for a Accepted Article remote review (confirming that a face-to-face consultation was not required), and her case was found to be safe for a remote consultation. In February 2020 she went skiing having previously been healthy. It was highly probable that she contracted COVID-19 at the beginning of March 2020, as she met with a friend who suffered from COVID-19 disease, and subsequent to that she herself developed problems with a loss of smell and taste and also the new onset of a severe dry cough. At this time routine COVID-19 testing was not available in the UK, but this does appear in retrospect to be the likely diagnosis. In May 2020 she had noticed pain in her anterior neck, in the region of the thyroid, radiating to the jaw and to the head. She also noticed a neck swelling, and she was referred to a local hospital by her GP for an urgent review. A thyroid ultrasound was arranged for her: it suggested possible thyroiditis on a background of a multinodular goitre (excluding thyroid cancer), and she was discharged back to her GP. She continued to have neck pain accompanied by a dry cough and a feeling as if she was needing to continually clear her throat. She started to feel tired and gain weight, but simultaneously felt hot, sweaty and constipated, had mood swings, was irritable, and had tremors and palpitations. All of these symptoms were absolutely new to her. Her GP arranged for assessment of thyroid function tests, which were consistent with thyroid over-activity. For the severe neck pain, she was treated with Ibuprofen 200mg three times per day and paracetamol 1g three times per day. We confirmed biochemical thyrotoxicosis, with positive anti-TPO and anti-Tg antibodies, while her TSH-R antibodies were negative. Her COVID-19 antibodies were positive. Her thyroid ultrasound ( Figure 1 ) showed a normal-sized thyroid with patchy areas of variably-reduced parenchymal echogenicity bilaterally, with typical ultrasound features of a subacute ('de Quervain's') thyroiditis, which was more extensive on the left than the right. The thyroid was tender during the examination. There were some spared areas with normal echogenicity, and two benign looking (U2) hyperechoic nodules measuring 6mm inferiorly on the right and 7mm superiorly on the left. Reactive left paratracheal lymph nodes were noted without pathological nodes elsewhere in the neck. Her technetium pertechnetate radionuclide thyroid scan showed poor tracer uptake within the neck and thyroid bed. The thyroid gland was not clearly visualised. Background activity was increased. The uptake function was reported at 0.1% (normal range 0.4-4%) and was compatible with subacute thyroiditis (SAT). We considered corticosteroid ('steroid') therapy, but she was not keen to start them due to the COVID-19 pandemic and preferred to manage her symptoms with simple analgesics and propranolol. Her thyroid function tests settled over a period of six weeks and she returned to the care of her GP. During follow-up in primary care she developed sub-clinical hypothyroidism, and low-dose thyroxine treatment was started with 25ug daily. In this case report we demonstrate that SAT seemed to follow infection with COVID-19, and as expected was self-limiting. It also illustrates how the delivery of health care has changed during the current pandemic (remote vs. face-to-face), possibly in a manner which will out-live the current situation. At present, the effect of acute COVID-19 on thyroid function in a population with no pre-existing thyroid disease is yet to be fully determined, as the reports are conflicting between thyrotoxicosis, euthyroidism and suppression of thyroid function [12] [13] [14] [15] . Recently, several case reports and series have been published on COVID-19-related SAT [16] [17] [18] [19] [20] [21] [22] [23] [24] . Other papers provide some insight into thyroid complications in or followed by COVID-19 disease including Graves' disease 25, 26 , Hashimoto's disease 27 , atypical thyroiditis 28 and 'painless thyroiditis' 29 , as well as post-partum thyroiditis following COVID-19 30 . assessed during the active infection and following recovery. They found a transient decease in TSH and fT3 whose severity corresponded to the severity of illness; however, the tests normalised after recovery. In particular, they found that TSH below the normal range was present in 56% (28/50) of the patients with COVID-19. The levels of TSH and serum total triiodothyronine (TT3) of the patients with COVID-19 were significantly lower than those of the healthy control group and non-COVID-19 pneumonia patients. The more severe the COVID-19, the lower were the levels of TSH and TT3 (p < 0.001). The total thyroxine (TT4) level of the patients with COVID-19 was not significantly different from the control group. None of the patients received thyroid hormone replacement therapy. On recovery, no significant differences in TSH, TT3, TT4, free triiodothyronine (fT3) or free Accepted Article thyroxine (fT4) levels were found between the COVID-19 and control groups 13 . The fact that the serum TSH levels of the patients with COVID-19 were significantly lower in the severe and critical group compared with non- Additionally, patchy SAT can be mistaken for multifocal malignancy due to the irregular hypoechoic nature of the parenchymal changes [32] [33] [34] [35] . The most common treatment in COVID-19-induced SAT included short term corticosteroids, -adrenoceptor blockers as well as analgesics [16] [17] [18] . In one case combination treatment of hydroxychloroquine and steroids was reported 20 , although hydroxychloroquine is not currently a recommended therapy. Steroids were used by other authors reporting COVID-19-related SAT for different reasons and timelines. In some cases, they were used from the disease onset, in some following revision of the diagnosis. In some cases (ours included) steroids were not used as the disease was mild and the patient declined this therapy. Subacute thyroiditis (SAT) is a clinical diagnosis of an inflammatory thyroid disorder thought to be of viral origin, generally preceded by an upper respiratory tract infection. Since the disorder is self-limiting, it is frequently under-diagnosed. However, the disease should not be overlooked since the associated thyrotoxicosis may worsen the clinical course of concomitant disorders (e.g., respiratory distress) and long-term sequelae, such as autoimmune hypothyroidism 19 . Evidence for viral infection in SAT has been linked to mumps virus, coxsackievirus, adenovirus, Epstein-Barr virus, rubella and cytomegalovirus, though a specific viral cause is not always This article is protected by copyright. All rights reserved found 18, 36 . It would appear that SARS-CoV-2 should be added to the list of viruses causing SAT. As this is still relatively new disease, it is too early to definitively say if COVID-19 related SAT differs from other viral-induced SAT in terms of severity, recovery, and longer-term sequelae. Our own experience though indicates a possible overlap between this type of postviral thyroiditis and auto-immune thyroid disease particularly with Grave's disease. Very recently, a single-blind, randomised controlled study addressing shortterm or 6-week prednisolone use in the treatment of non-COVID-19 related SAT has been published (patients enrolled to the trial developed SAT between 2013 and 2014). The study showed fewer side effects of glucocorticoids but similar efficacy and recurrence rates with short-term prednisone compared with the 6-week treatment for SAT. The authors concluded that short-term prednisone with a better safety profile may be an alternative strategy for ameliorating moderate-to-severe symptoms of SAT 37 . However, in our experience we would generally recommend steroids in the treatment of COVID-19-related SAT when appropriate and safe, after discussing with the patient the risks and benefits of this therapy. However, we would start with non-steroidal anti-inflammatory drugs and possibly propranolol, and reserve steroids for patients with severe persisting pain. 18 . A recent study also suggested a Accepted Article possible genetic predisposition to SAT in association with not only HLA-B*35 but also HLA-B*18:01, -DRB1*01 and -C*04:01 38 . Much has been discussed regarding ACE-2, which is key to the mechanism of SARS-CoV-2 infection with the virus using it as a host cell receptor to invade human cells. Studies based on SARS-CoV-2 in 2020 have shown that ACE-2 expression levels are highest in the thyroid compared to other organs, such as the small intestine, kidneys, heart and adipose tissue, which does suggest a plausible mechanism for the pathophysiology of thyroiditis in COVID-19 (summarised by Mattar et al.) 18 . The main challenge with SAT during the COVID-19 pandemic is a potential need to use corticosteroids; however, in nearly all case reports SAT occurred some months after COVID-19 illness. As noted above, retrospective studies actually showed that thyroid function tests during active COVID-19-19 disease remain either normal or similar to the sick euthyroid syndrome. A new manner of care delivery via remote consultations has become extremely popular (over the telephone or video) after initial endorsing (when appropriate) by the UK General Medical Council (https://www.gmcuk.org/ethical-guidance/ethical-hub/remote-consultations) as well as the European Society for Endocrinology 1,5,6,10 . Our patient was initially referred within the 'two-week cancer pathway' but once cancer was excluded, she was referred and accepted for the remote consultation, which seemed safe in that case scenario. Nevertheless, investigations such as ultrasound and radionuclide scanning do require a patient visit, with implications for personal protective equipment and infection control in service departments Accepted Article during a period of reduced access to radiology (secondary to redeployment and staff absences) 39, 40 . This article is protected by copyright. All rights reserved Table 1 . Biochemistry. Patient presented with mild biochemical thyrotoxicosis on the background of positive anti -TPO and anti-Tg antibodies but negative TSH-R antibodies. CRP and ESR were mildly elevated but her full blood count (FBC) and liver function tests (LFTs), as well as the renal profile were within normal limits. COVID-19 IgG antibodies were positive. *Result from GP at the time of the referral (please note some differences between normal ranges between laboratories where the blood tests were conducted). Abbreviations: thyroid-stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), thyroid peroxi dase antibodies COVID-19 and endocrine diseases. A statement from the HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic Editorial: The COVID-19 pandemic requires a unified global response Our Response to COVID-19 as Endocrinologists and Diabetologists Managing common endocrine disorders amid COVID-19 pandemic Endocrinology in the time of COVID-19: Diagnosis and Management of Gestational Diabetes Mellitus Thyroid disease in the time of COVID-19 ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism Thyroid function before, during and after COVID-19 Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study Thyrotoxicosis in patients with COVID-19: the THYRCOV study Accepted Article This article is protected by copyright. All rights reserved 15 Euthyroid Sick Syndrome in Patients With COVID-19 Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series Subacute Thyroiditis After Sars-COV-2 Infection Subacute thyroiditis associated with COVID-19 Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. Hormones (Athens) A case of subacute thyroiditis associated with Covid-19 infection SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report Subacute Thyroiditis Associated with COVID-19 Subacute Thyroiditis in the Setting of Coronavirus Disease 2019 Subacute thyroiditis might be a complication triggered by SARS-CoV-2. Endocrinol Diabetes Nutr Graves' disease insights from a review of the Johns Hopkins surgical pathology archive SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19 COVID-19 complicated by Hashimoto's thyroiditis Accepted Article This article is protected by copyright. All rights reserved 28 SARS-CoV-2-related atypical thyroiditis Painless thyroiditis in SARS-CoV-2 infection. Endocrinol Diabetes Nutr A case of postpartum thyroiditis following SARS-CoV-2 infection Thyroid function in critically ill patients Sonographic Characteristics and Interval Changes of Subacute Thyroiditis Papillary thyroid carcinomas are highly obscured by inflammatory hypoechoic regions caused by subacute thyroiditis: a longitudinal evaluation of 710 patients using ultrasonography The contribution of ultrasonographic findings to the prognosis of subacute thyroiditis Thyroid primary and metastatic malignant tumours of poor prognosis may mimic subacute thyroiditis -time to change the diagnostic criteria: case reports and a review of the literature A Case of Subacute Thyroiditis Associated with Erythrovirus B19 Infection Short-Term Versus 6-Week Prednisone in the Treatment of Subacute Thyroiditis: A Randomized Controlled Trial. Endocr Pract. 2020:Online ahead of print Subacute Thyroiditis is Associated with HLA-B*18:01, -DRB1*01 and -C*04:01-The Significance of the New Molecular Background Nuclear thyroidology in pandemic times: The paradigm shift of COVID-19 This article is protected by copyright. All rights reserved